Hexabromobenzene was used in a study investigating its metabolic fate in female rats, wherein the substance was orally administered at doses of 16.6 mg/kg body weight every other day for a span of 2 weeks.

Analysis of the rats' excreta revealed the presence of various metabolites, including unchanged HBB, pentabromobenzene, as well as oxygen- and sulfur-containing compounds.

[9] Hexabromobenzene poses significant dangers due to its toxicity profile as classified by the GHS (Globally Harmonized System of Classification and Labeling of Chemicals).

Classified as GHS07, HBB exhibits acute toxicity via oral, dermal, and inhalation routes, categorizing it under category 4 for this hazard.

There are severe health risks associated with HBB exposure, warranting careful handling and stringent safety measures in its use and management.